Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioMarin PharmaceuticalMEX:BMRN 80 Return-on-Tangible-Asset is 5.49% as of Mar. 2026, which is 478% above its 10-year median of 0.95. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,514.38 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,413 Biotechnology companies, BioMarin Pharmaceutical ranks better than 85.49% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. BioMarin Pharmaceutical's annualizedNet Income for the quarter that ended in Mar. 2026 was MXN7,612 Mil. BioMarin Pharmaceutical's average total tangible assets for the quarter that ended in Mar. 2026 was MXN138,522 Mil. Therefore, BioMarin Pharmaceutical's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 5.49%.
The historical rank and industry rank for BioMarin Pharmaceutical's Return-on-Tangible-Asset or its related term are showing as below:
MEX:BMRN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -20.59 Med: 0.95 Max: 18.42
Current: 3.7
During the past 13 years, BioMarin Pharmaceutical's highest Return-on-Tangible-Asset was 18.42%. The lowest was -20.59%. And the median was 0.95%.
MEX:BMRN's Return-on-Tangible-Asset is ranked better than 85.49% of 1413
companies
in the Biotechnology industry
Industry Median: -35.75
vs MEX:BMRN: 3.70
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
BioMarin Pharmaceutical Return-on-Tangible-Asset Related Terms
BioMarin Pharmaceutical Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for BioMarin Pharmaceutical's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BMRN vs TECH, CYTK, SMMT: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 5.49% mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Return-on-Tangible-Asset of 5.49% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BioMarin Pharmaceutical and its competitors. This is 478% above median its historical median of 0.95. According to the industry distribution chart, BioMarin Pharmaceutical ranks #205 out of 1413 companies in the Biotechnology industry, placing it in the top 14.5%.
Is BioMarin Pharmaceutical's Return-on-Tangible-Asset too high?
BioMarin Pharmaceutical's current Return-on-Tangible-Asset of 5.49% is 478% above median its 10-year median of 0.95. Based on the distribution chart, BioMarin Pharmaceutical ranks #205 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Return-on-Tangible-Asset compare to TECH and CYTK?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #205 out of 1413 companies for Return-on-Tangible-Asset. This places BioMarin Pharmaceutical in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Return-on-Tangible-Asset is 5.49%, which is 478% above median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,514.38, compared to a current price of MXN959.00 — trading 36.7% below its estimated fair value. The current Return-on-Tangible-Asset is 5.49%, which is 478% above median its 10-year median of 0.95. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Return-on-Tangible-Asset is 5.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of MXN959.00 is trading 36.7% below its estimated GF Value™ of MXN1,514.38.
GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.
Key valuation signals for MEX:BMRN:
Return-on-Tangible-Asset: 5.49% (478% above median its 10-year median of 0.95)
GF Value™: MXN1,514.38 vs. price of MXN959.00 (36.7% below fair value)
No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score
Get the complete analysis for MEX:BMRN
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BMRN has been successfully added to your 
